<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555943</url>
  </required_header>
  <id_info>
    <org_study_id>H&amp;H_DASCO</org_study_id>
    <nct_id>NCT02555943</nct_id>
  </id_info>
  <brief_title>DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)</brief_title>
  <acronym>DASCO</acronym>
  <official_title>Direct Antiviral Agents for the Treatment of Chronic HCV/HBV Co-infection Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanity and Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanity and Health Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study to determine the incidence, morbidity, mortality and predisposing
      factors for the reactivation of hepatitis B virus replication during direct anti-HCV
      treatment of HCV/HBV co-infection patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who receive direct-acting anti-HCV treatment will be prospectively studied during
      2-year period. All patients have HCV/HBV co-infection.

      The inclusion/exclusion criteria and the follow up plan will be listed in following part.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who experience virological breakthrough</measure>
    <time_frame>From the commencement of DAAs treatment to 12 weeks post DAAs treatment</time_frame>
    <description>Virological breakthrough is defined as 1 logIU/ml increase during and/or post DAAs treatment for the baseline or nadir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants who experience virological rebound</measure>
    <time_frame>From the commencement of DAAs treatment to 12 weeks post DAAs treatment</time_frame>
    <description>Virological rebound is defined as 2 logIU/ml increase during and/or post DAAs treatment for the baseline or nadir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participant who experience biochemical rebound</measure>
    <time_frame>From the commencement of DAAs treatment to 12 weeks post DAAs treatment</time_frame>
    <description>Biochemical rebound is defined as</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of participant who experience liver failure</measure>
    <time_frame>From the commencement of DAAs treatment to 12 weeks post DAAs treatment</time_frame>
    <description>Diagnosis of liver failure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <condition>HBV Coinfection</condition>
  <condition>Hepatitis B Reactivation</condition>
  <arm_group>
    <arm_group_label>Prophylactic/Early anti-HBV treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection before or at the commencement of direct anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred anti-HBV treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection when HBV viral breakthrough occurred during anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir/Sofosbuvir</intervention_name>
    <description>Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.</description>
    <arm_group_label>Prophylactic/Early anti-HBV treatment</arm_group_label>
    <arm_group_label>Deferred anti-HBV treatment</arm_group_label>
    <other_name>Harvoni®</other_name>
    <other_name>GS-7977</other_name>
    <other_name>GS-5885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir and Daclatasvir</intervention_name>
    <description>TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.</description>
    <arm_group_label>Prophylactic/Early anti-HBV treatment</arm_group_label>
    <arm_group_label>Deferred anti-HBV treatment</arm_group_label>
    <other_name>Sovaldi®, GS-7977</other_name>
    <other_name>Daklinza®,BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir</intervention_name>
    <description>VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.</description>
    <arm_group_label>Prophylactic/Early anti-HBV treatment</arm_group_label>
    <arm_group_label>Deferred anti-HBV treatment</arm_group_label>
    <other_name>VIEKIRA PAK™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.</description>
    <arm_group_label>Prophylactic/Early anti-HBV treatment</arm_group_label>
    <arm_group_label>Deferred anti-HBV treatment</arm_group_label>
    <other_name>BARACLUDE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.</description>
    <arm_group_label>Prophylactic/Early anti-HBV treatment</arm_group_label>
    <arm_group_label>Deferred anti-HBV treatment</arm_group_label>
    <other_name>VIREAD®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA positive,

          -  HBsAg positive with detectable or undetectable HBV DNA,

          -  Receiving pan oral direct-acting anti-HCV regimen

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner;

          -  HIV infection;

          -  Hematologic or biochemical parameters at Screening outside the protocol- specified
             requirements;

          -  Active or recent history (≤ 1 year) of drug or alcohol abuse;

          -  History or current evidence of any condition, therapy, laboratory abnormality or other
             circumstance that might confound the results of the study, or interfere with the
             subject's participation for the full duration of the study, such that it is not in the
             best interest of the subject to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Lau, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanity and Health GI and Liver Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng Wang, M.D. PhD</last_name>
    <phone>(852)28613777</phone>
    <email>doc_chengwang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George Lau, M.D.</last_name>
    <phone>(852)28613777</phone>
    <email>gkklau@netvigator.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Humanity and Health GI and Liver Centre</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <zip>00852</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Wang, M.D. PhD</last_name>
      <phone>(852)28613777</phone>
      <email>doc_chengwang@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yudong Wang</last_name>
      <phone>(852)28613777</phone>
      <email>ydwang@connect.hku.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2015</study_first_submitted>
  <study_first_submitted_qc>September 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Humanity and Health Research Centre</investigator_affiliation>
    <investigator_full_name>George Lau</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Hepatitis C Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

